John Heymach, MD, PhD

John V. Heymach, MD, PhD, discusses the activity of zongertinib in patients with previously treated advanced HER2-mutant NSCLC.

John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.

John Heymach, MD, PhD, discusses perioperative durvalumab in patients with resectable non-small cell lung cancer.

John V. Heymach, MD, PhD, discusses findings the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.

Expert oncologist John Heymach, MD, PhD, addresses the potential role of immunotherapy in concomitant KRAS/TP53-mutated NSCLC.

Insight on the potential role of immunotherapy in patients with NSCLC and concomitant KRAS/STK11 or KRAS/KEAP1 mutations.

John Heymach, MD, PhD, discusses the poor outcomes that have been observed with immunotherapy in patients with NSCLC and EGFR mutations or ALK rearrangements.

Expert perspectives on the prevalence of molecular profiling in NSCLC, and the unmet needs and barriers preventing the uptake of routine molecular testing.

A brief discussion on insufficient tissue results in molecular profiling for NSCLC and how this can be avoided or addressed via liquid biopsy.

Expert oncologist John Heymach, MD, PhD, provides comprehensive insight on testing strategies for actionable mutations in NSCLC.

John V. Heymach, MD, PhD, discusses the future of immunotherapy in patients with non–small cell lung cancer.

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.